Q-omics provides the consensus-scored PLSCR3 profile across patient tissues and cancer cell-line models. PLSCR3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PLSCR3 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, PLSCR3 RNA expression shows 18,123 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where PLSCR3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLSCR3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLSCR3 survival associations across molecular data types. PLSCR3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLSCR3 RNA expression–survival associations across cancer types. High PLSCR3 expression shows unfavorable associations in MESO, KIRC, UCEC, UVM and LGG, but favorable associations in BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PLSCR3 RNA expression.
This table summarizes PLSCR3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PLSCR3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLSCR3 shows lower tumor expression in KICH and BRCA and higher tumor expression in HNSC, KIRC, COAD and STAD. The HNSC box plot shows higher PLSCR3 RNA expression in tumor versus normal tissue (log2 FC = +0.720, t-test p < 0.001).
This table shows molecular features associated with PLSCR3 in patient tissues and cancer cell lines. In patient samples, PLSCR3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLSCR3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
